Revelation Biosciences, Inc. Share Price Nasdaq
Equities
REVBU
US76135L2007
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.82M 221M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.68% |
Managers | Title | Age | Since |
---|---|---|---|
James Rolke
CEO | Chief Executive Officer | 55 | 30/04/20 |
Chester Zygmont
DFI | Director of Finance/CFO | 44 | 30/04/20 |
Sandra Vedrick
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
George Tidmarsh
CHM | Chairman | 64 | 30/04/20 |
Jess Roper
BRD | Director/Board Member | 59 | 30/09/20 |
James Rolke
CEO | Chief Executive Officer | 55 | 30/04/20 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |